Michael Gallatin, Ph.D.

Former Vice President and Scientific Director of ICOS Corporation

Michael Gallatin, Ph.D., is a former Vice President and Scientific Director of ICOS Corporation, where his responsibilities included discovery, preclinical research, medicinal chemistry and process chemistry groups, including those responsible for worldwide development and launch of Tadalafil (Cialis®). Subsequently, Dr. Gallatin co-founded Stromedix, which focused on novel treatments for chronic fibrotic diseases and was recently acquired by Biogen Idec. Dr. Gallatin also co-founded and was president of Calistoga Pharmaceuticals, the first company to demonstrate clinical benefit of isoform-selective PI3 kinase inhibition, subsequently acquired by Gilead.  He has also been a member of the Scientific Advisory Boards of the Keystone Symposia, Caprion, and the University of Texas Department of Chemistry, a member of the BioSeek Board of Directors and has recently also joined the Board of Directors of the Benaroya Research Institute.  Dr. Gallatin received his Ph.D. from the University of Alberta’s Department of Immunology, and discovered the first cell adhesion molecule implicated in site-selective leukocyte traffic while a Damon Runyon-Walter Winchell and American Cancer Society fellow at Stanford University in the laboratory of Dr. Irving Weissman. Dr. Gallatin is a former faculty member of the Fred Hutchinson Cancer Center and is currently a senior advisor to Frazier Healthcare.